FDA approves two more generic Saxenda products on the same day

The U.S. Food and Drug Administration approved two more generic liraglutide injection applications on the same day, February 24, 2026 — one from Biocon Pharma (ANDA217063) and one from Orbicular Pharmaceutical Technologies (ANDA217234) ^[1][2]. Both are copies of the daily GLP-1 injection sold under the brand name Saxenda.

Liraglutide is an older member of the same drug class as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). Both new approvals are classified by the FDA as GLP-1 receptor agonists ^[1][2].

What the FDA records show

Biocon's application, ANDA217063, was an original submission with a standard review priority, and its status was listed as approved with a status date of February 24, 2026 ^[1]. The product is liraglutide solution for subcutaneous (under the skin) injection at a strength of 18 mg per 3 mL, or 6 mg per mL, with two package codes listed under NDC 70377-095 ^[1].

Orbicular's application, ANDA217234, carries the same approval date, the same standard review priority, and the same product strength of 18 mg per 3 mL ^[2]. The FDA record lists two manufacturers tied to that application — Orbicular Pharmaceutical Technologies Private Limited and Cipla USA Inc. — and five package codes across two product codes, 81607-019 and 69097-910 ^[2]. In practice, that points to Cipla USA as the U.S. distributor for the Orbicular product.

Both products carry the therapeutic equivalence code AP2 and are listed with a marketing status of "Prescription" ^[1][2]. An "A" therapeutic equivalence code means the FDA considers the product substitutable for its reference brand; state pharmacy substitution rules determine how that plays out at the counter.

One caveat on the records themselves: the openFDA entries list the active ingredient, strength, route and sponsor, but they do not name the brand-name reference product ^[1][2]. The 18 mg/3 mL strength is used by more than one liraglutide brand, so the specific reference listing is not spelled out in the data provided here. The approvals are also reported to bring the number of Saxenda-referenced liraglutide applications to three; the records for a third application were not included in these sources, so that count cannot be verified from the data above.

Why it matters for patients

Generic competition is the main mechanism that lowers drug prices in the United States, and the GLP-1 class has been almost entirely brand-only. Liraglutide is the first GLP-1 medicine to face real generic entry, and each additional approved application adds another possible supplier.

But an approval is not the same as a product on the shelf. The FDA records show these applications were approved on February 24, 2026 ^[1][2]; they do not say when either company will actually ship product, how much it will cost, or whether insurers will cover it. Those details are not yet known from these sources.

It is also worth being precise about what liraglutide is. It is a once-daily injection, unlike the weekly semaglutide and tirzepatide products, and clinical trial results for the newer weekly drugs have generally shown larger average weight loss. A cheaper liraglutide option does not make it interchangeable with Wegovy or Zepbound — those are different molecules with different approvals, dosing and prices. Only a prescriber can judge whether a switch makes sense for a given person.

For people whose plans do not cover a branded GLP-1, though, a generic daily injection that pharmacies can substitute could become a more affordable path. Whether that happens depends on launch timing and list pricing, neither of which is in the record.

What happens next

• February 24, 2026: FDA approves ANDA217063 (Biocon Pharma) and ANDA217234 (Orbicular, with Cipla USA listed as a manufacturer) ^[1][2].
• Not yet announced: launch dates, pricing and pharmacy availability for either product. Patients and prescribers will learn about supply through wholesalers and pharmacy systems as the National Drug Codes listed in the FDA records begin to appear in stock ^[1][2].